Literature DB >> 1827636

Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis.

E A Hellen1, D C Rowlands, T T Hansel, G D Kitas, J Crocker.   

Abstract

The leucocyte antigen CD23 is expressed by B lymphocytes following activation by a number of stimuli and functions as an IgE receptor, and in its soluble form, as a putative B cell growth factor. The expression of CD23 on the surface of lymphocytes in paraffin wax sections of synovial biopsy specimens was studied using a novel mouse monoclonal antibody, BU38. Specimens were investigated from nine cases of rheumatoid arthritis, six cases of osteoarthritis, and eight cases of chronic inflammation in articular and non-articular tissues. CD23 was expressed on a high proportion of lymphocytes in all forms of chronic inflammation and was not specific for rheumatoid arthritis. It may be a characteristic feature of any chronic inflammatory response. As CD23 was found on the surface of lymphocytes in many cases of these arthritides, sCD23 in serum or synovial fluid may yet prove a useful marker for the severity of the inflammatory infiltrate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827636      PMCID: PMC496901          DOI: 10.1136/jcp.44.4.293

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  28 in total

1.  Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary macrophage activating factor.

Authors:  G S Firestein; N J Zvaifler
Journal:  Arthritis Rheum       Date:  1987-08

2.  Insertion of a multispanning membrane protein occurs sequentially and requires only one signal sequence.

Authors:  H P Wessels; M Spiess
Journal:  Cell       Date:  1988-10-07       Impact factor: 41.582

3.  Ligation of the CD23,p45 (BLAST-2,EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes.

Authors:  J Gordon; M Rowe; L Walker; G Guy
Journal:  Eur J Immunol       Date:  1986-09       Impact factor: 5.532

4.  Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti-Bp50 (CDw40).

Authors:  J Cairns; L Flores-Romo; M J Millsum; G R Guy; S Gillis; J A Ledbetter; J Gordon
Journal:  Eur J Immunol       Date:  1988-03       Impact factor: 5.532

5.  Biochemical analysis suggests distinct functional roles for the BLAST-1 and BLAST-2 antigens.

Authors:  D A Thorley-Lawson; S L Swendeman; C M Edson
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

6.  Dw subtypes of DR4 in rheumatoid arthritis: evidence for a preferential association with Dw4.

Authors:  D Zoschke; M Segall
Journal:  Hum Immunol       Date:  1986-01       Impact factor: 2.850

7.  Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.

Authors:  P Stastny
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

8.  Recombinant soluble Fc epsilon receptor II (Fc epsilon RII/CD23) has IgE binding activity but no B cell growth promoting activity.

Authors:  N Uchibayashi; H Kikutani; E L Barsumian; R Hauptmann; F J Schneider; R Schwendenwein; W Sommergruber; W Spevak; I Maurer-Fogy; M Suemura
Journal:  J Immunol       Date:  1989-06-01       Impact factor: 5.422

9.  Molecular structure of human lymphocyte receptor for immunoglobulin E.

Authors:  H Kikutani; S Inui; R Sato; E L Barsumian; H Owaki; K Yamasaki; T Kaisho; N Uchibayashi; R R Hardy; T Hirano
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

10.  Early events in Epstein-Barr virus infection provide a model for B cell activation.

Authors:  D A Thorley-Lawson; K P Mann
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  5 in total

1.  Structure-based modeling of the ligand binding domain of the human cell surface receptor CD23 and comparison of two independently derived molecular models.

Authors:  J Bajorath; A Aruffo
Journal:  Protein Sci       Date:  1996-02       Impact factor: 6.725

2.  Increased synovial fluid levels of soluble CD23 are associated with an erosive status in rheumatoid arthritis (RA).

Authors:  C Ribbens; V Bonnet; M J Kaiser; B Andre; O Kaye; N Franchimont; D de Groote; Y Beguin; M G Malaise
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

3.  Expression of FCepsilonII/CD23 on human neutrophils isolated from rheumatoid arthritis patients.

Authors:  A Vella; P Bellavite; A Adami; R Ortolani; G Benoni; A Carletto; D Biasi; P Caramaschi; G Tridente
Journal:  Inflammation       Date:  1999-10       Impact factor: 4.092

4.  Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI 129471.

Authors:  D J Wheeler; S Parveen; K Pollock; R J Williams
Journal:  Immunology       Date:  1998-09       Impact factor: 7.397

5.  Regulation of cytokine production by soluble CD23: costimulation of interferon gamma secretion and triggering of tumor necrosis factor alpha release.

Authors:  M Armant; H Ishihara; M Rubio; G Delespesse; M Sarfati
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.